Compare Lennar Corporation (LEN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance

Lennar CorporationTrade

Royalty Pharma plc Class A Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Lennar Corporation vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Lennar Corporation trades at $76.71 (market cap $18.44B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.95 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and Lennar Corporation pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.

	LEN	RPRX
Market Cap	$18.44B	$25.27B
Volume	6,012,214	3,671,183
Sector	Consumer Cyclical	Health
52-Week High	$133.13	$63.96
52-Week Low	$74.44	$35.44
Typical Hold Time	67 Days	1 Days
Enterprise Value	$22.86B	$32.50B
Dividend Yield	2.58%	1.66%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lennar Corporation

LEN trades at $76.69, up 0.74% on the day, with a bearish technical signal from moving averages and oscillators. Recent earnings show three consecutive quarterly misses against expectations, with Q3 2026 results pending. Revenue declined to $34.19B in 2025 from $35.4B in 2024, while net income fell to $2.08B. Valuation metrics appear attractive with P/E of 14.7 and P/B of 0.86. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.

The stock presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability and housing market challenges. Near-term risks include potential earnings volatility and high mortgage rates, while long-term prospects benefit from Berkshire's strategic positioning and the company's asset-light transition.

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LEN

Block & Leviton probes Lennar over possible misleading home delivery reports affecting investors.Newsfile Corp · 1 day agoBearish Millrose Properties faces $1.4B market cap loss after rental pivot triggers short-seller reportSeeking Alpha · 2 days agoBullish 30-year mortgage rates near 7.5%, raising monthly costs and pressuring homebuilders to cut margins.24/7 Wall Street · 2 days agoBearish View details →

RPRX

Royalty Pharma to release Q3 2026 earnings on Nov 4 with live webcast and call.GlobeNewsWire · 12 hours agoNeutral View details →

About Lennar Corporation

Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.